Xcopri
Named-patient access overview. Xcopri is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Xcopri (cenobamate) is an oral antiseizure medication approved by the US Food and Drug Administration in November 2019 for the treatment of focal-onset (partial-onset) seizures in adults. The product is marketed approximately by SK Life Science, the US subsidiary of SK Biopharmaceuticals. Cenobamate has a dual mechanism with sodium-channel inactivation and positive allosteric modulation of GABA-A receptors, and clinical trial data show high rates of seizure freedom in patients with treatment-resistant focal epilepsy at maintenance doses.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Xcopri
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Xcopri is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Xcopri in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Xcopri
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.